The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...

Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...

But all of those promises have turned out to be overstated or simply wrong. Legalization has raised cannabis consumption ...

This study examined the important question of how neurons code temporal information across the hippocampus, dorsal striatum, and orbitofrontal cortex. Using a behavioral task in the rat that requires ...

A new opioid database could provide some with a brand-new start to 2025.The Charleston Center recently released a real-time ...

Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...